AEON Biopharma, Inc. Operating Income Loss

Quick Answer

AEON Biopharma, Inc. reported Operating Income Loss of -$12.80 million for the year ending 2025.

  • AEON Biopharma, Inc. showed a decrease of -117.5% in Operating Income Loss from 2024 to 2025.
  • This data is from AEON Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
  • XBRL data for this metric is available from 2020 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 5 years of available data (2020 to 2025), AEON Biopharma, Inc.'s Operating Income Loss has declined by 356,728.3%.
  • Historical annual values: Fiscal year 2025: -$12.80 million | Fiscal year 2024: $72.99 million | Fiscal year 2022: -$48.43 million | Fiscal year 2021: -$1.94 million | Fiscal year 2020: -$3.6 thousand.
  • Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: